Scarica l'app Stockscreener
2.355
3.09%
-0.075
Dopo l'orario di chiusura:
2.35
-0.005
-0.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Precedente Chiudi:
$2.43
Aprire:
$2.43
Volume 24 ore:
1.94M
Relative Volume:
2.90
Capitalizzazione di mercato:
$299.80M
Reddito:
$45.44M
Utile/perdita netta:
$-35.43M
Rapporto P/E:
-6.9265
EPS:
-0.34
Flusso di cassa netto:
$-25.39M
1 W Prestazione:
-16.49%
1M Prestazione:
-6.92%
6M Prestazione:
-30.43%
1 anno Prestazione:
-50.21%
Intervallo 1D:
$2.29
$2.43
Intervallo di 1 settimana:
$2.29
$2.86
Portata 52W:
$2.21
$5.26
Maxcyte Inc Stock (MXCT) Company Profile
Nome
Maxcyte Inc
Settore
Industria
Telefono
301-517-5556
Indirizzo
9713 KEY WEST AVENUE,, ROCKVILLE
Confronta MXCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.355 | 299.80M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-29 | Iniziato | Craig Hallum | Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-24 | Iniziato | BTIG Research | Buy |
| 2021-08-24 | Iniziato | Cowen | Outperform |
| 2021-08-24 | Iniziato | Stephens | Overweight |
| 2021-08-24 | Iniziato | Stifel | Buy |
| 2021-08-24 | Iniziato | Wedbush | Outperform |
| 2021-08-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Maxcyte Inc Borsa (MXCT) Ultime notizie
MaxCyte Files Form 10-Q for Q1 2025 - TipRanks
BTIG cuts MaxCyte stock price target to $5, maintains Buy rating - Investing.com
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - MSN
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know - MSN
Earnings call transcript: MaxCyte Q1 2025 beats revenue forecast, stock reacts - Investing.com
Wells Fargo & Company MN Boosts Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MaxCyte Reports Q1 2025 Financial Results Amid Revenue Dip - TipRanks
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance - The Manila Times
MaxCyte reports Q1 EPS (10c), consensus (10c) - TipRanks
Financial Fitness Check: Examining MaxCyte Inc (MXCT)’s Key Ratios - DWinneX
A Look at MaxCyte's Upcoming Earnings Report - Nasdaq
MaxCyte Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Invesco Ltd. Has $204,000 Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday - Defense World
MaxCyte, Inc. (NASDAQ:MXCT) Position Trimmed by Legal & General Group Plc - Defense World
MaxCyte Expands Stock Capital with New Share Issuance - TipRanks
Upward Trajectory: MaxCyte Inc (MXCT) Posts a Slidee, Closing at 2.84 - DWinneX
A stock that deserves closer examination: MaxCyte Inc (MXCT) - uspostnews.com
Renaissance Technologies LLC Has $1.17 Million Stock Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by JPMorgan Chase & Co. - Defense World
MaxCyte Announces AIM Delisting to Focus on NASDAQ - TipRanks
MaxCyte Inc (MXCT) requires closer examination - uspostnews.com
BlackRock Adjusts Stake in MaxCyte, Inc. - TipRanks
MaxCyte Announces Change in Major Shareholder Holdings - TipRanks
Vanguard Group Inc. Sells 345,587 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
Cooley Advises Cell Therapy Biz On London Market Exit - Law360
MaxCyte intends to delist from London's AIM to enhance liquidity - marketscreener.com
MaxCyte to Delist from AIM, Focus on Nasdaq - TipRanks
MaxCyte Announces Change in Voting Rights Structure - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Stock Holdings Lifted by American Century Companies Inc. - Defense World
MaxCyte stock plunges to 52-week low of $2.25 amid market challenges By Investing.com - Investing.com South Africa
MaxCyte stock plunges to 52-week low of $2.25 amid market challenges - Investing.com India
MaxCyte sets date for Q1 2025 financial results reveal By Investing.com - Investing.com South Africa
MaxCyte sets date for Q1 2025 financial results reveal - Investing.com
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - The Manila Times
MaxCyte to Announce Q1 2025 Financial Results - TipRanks
Insider Buyers Lose US$201k As MaxCyte Sheds UK£32m - simplywall.st
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) - Yahoo Finance
With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns - Yahoo Finance
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround - Yahoo Finance
MaxCyte Inc (MXCT) Volatility Hits 6.24% – Here Is What You Should Do - Stocksregister
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges - Investing.com Australia
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges By Investing.com - Investing.com South Africa
Maxcyte Inc Azioni (MXCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):